Related Experiment Video
Updated: Aug 12, 2026

Colon Ascendens Stent Peritonitis (CASP) - a Standardized Model for Polymicrobial Abdominal Sepsis
Published on: December 18, 2010
Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation
Basilia Zingarelli1, James A Cook
1Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center and the College of Medicine, University of Cincinnati, Cincinnati, Ohio 45229, USA. basilia.zingarelli@cchmc.org
Abstract:
Peroxisome proliferator-activated receptor-gamma (PPARgamma) is a member of the nuclear receptor superfamily and a ligand-activated transcription factor with pleiotropic effects on lipid metabolism, inflammation, and cell proliferation. PPARgamma forms a heterodimer with the retinoid X receptor and upon ligand-activation binds to the PPAR response element in the promoter of genes to allow transcription. The class of insulin-sensitizing drugs known as thiazolidinediones have been identified as specific PPARgamma agonists that have allowed the characterization of many genes regulated by PPARgamma. Thiazolidinediones include rosiglitazone, pioglitazone, troglitazone, and ciglitazone. In addition to these synthetic agonists, cyclopentenone prostaglandins of the J2 series have been identified as natural ligands for PPARgamma. Several in vitro and in vivo studies have demonstrated that pharmacological activation of PPARgamma by 15-deoxy-Delta(12,14)-PGJ2 (15d-PGJ2) or thiazolidinediones has anti-inflammatory effects. This article provides an overview of the role of PPARgamma in regulating the inflammatory response and emphasizes the potential efficacy of PPARgamma ligands as novel therapeutic approaches beyond diabetes in sepsis, inflammation, and reperfusion injury.
Insights
Peroxisome proliferator-activated receptor-gamma (PPARgamma) ligands, like thiazolidinediones, show anti-inflammatory effects. These compounds offer potential therapeutic uses beyond diabetes for conditions such as sepsis and reperfusion injury.
Area of Science:
- Molecular Biology
- Endocrinology
- Pharmacology
Background:
- Peroxisome proliferator-activated receptor-gamma (PPARgamma) is a nuclear receptor regulating lipid metabolism, inflammation, and cell proliferation.
- PPARgamma forms heterodimers with retinoid X receptor, binding DNA to modulate gene transcription upon ligand activation.
- Thiazolidinediones are synthetic PPARgamma agonists used to study its gene regulation.
Purpose of the Study:
- To provide an overview of PPARgamma's role in inflammatory response regulation.
- To highlight the therapeutic potential of PPARgamma ligands beyond diabetes treatment.
Main Methods:
- Review of in vitro and in vivo studies on PPARgamma activation.
- Characterization of genes regulated by PPARgamma using thiazolidinediones.
- Identification of natural ligands like J2 series cyclopentenone prostaglandins.
Main Results:
- Pharmacological activation of PPARgamma by 15-deoxy-Delta(12,14)-PGJ2 or thiazolidinediones demonstrates anti-inflammatory effects.
- PPARgamma plays a key role in modulating inflammatory pathways.
- Synthetic and natural ligands effectively activate PPARgamma.
Conclusions:
- PPARgamma ligands exhibit significant anti-inflammatory properties.
- PPARgamma agonists represent promising therapeutic strategies for inflammatory diseases.
- Potential applications include sepsis, inflammation, and reperfusion injury beyond glycemic control.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Peroxisomes
Regulation of the Unfolded Protein Response
GPCR Desensitization
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

